Alder Biopharmaceuticals (ALDR) Stock Price Down 3%

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) shares fell 3% on Thursday . The company traded as low as $11.15 and last traded at $11.20. 1,517,063 shares changed hands during trading, a decline of 15% from the average session volume of 1,779,517 shares. The stock had previously closed at $11.55.

A number of research firms have weighed in on ALDR. BidaskClub lowered shares of Alder Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. Zacks Investment Research raised shares of Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 1st. Leerink Swann reissued an “outperform” rating on shares of Alder Biopharmaceuticals in a research report on Sunday, March 4th. BMO Capital Markets reissued a “buy” rating and set a $22.00 target price on shares of Alder Biopharmaceuticals in a research report on Wednesday, January 3rd. Finally, ValuEngine raised shares of Alder Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company’s stock. Alder Biopharmaceuticals presently has an average rating of “Buy” and a consensus target price of $28.14.

How to Become a New Pot Stock Millionaire

The firm has a market capitalization of $783.61, a PE ratio of -2.17 and a beta of 2.51.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.03) by $0.23. The company had revenue of $0.94 million for the quarter. During the same period in the prior year, the company earned ($0.97) earnings per share. sell-side analysts expect that Alder Biopharmaceuticals Inc will post -4.25 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in ALDR. SG Americas Securities LLC acquired a new position in shares of Alder Biopharmaceuticals during the fourth quarter valued at about $132,000. Jane Street Group LLC acquired a new position in Alder Biopharmaceuticals in the third quarter worth about $184,000. Paloma Partners Management Co acquired a new position in Alder Biopharmaceuticals in the fourth quarter worth about $222,000. Teacher Retirement System of Texas acquired a new position in Alder Biopharmaceuticals in the fourth quarter worth about $231,000. Finally, Cubist Systematic Strategies LLC raised its position in Alder Biopharmaceuticals by 611.7% in the third quarter. Cubist Systematic Strategies LLC now owns 23,373 shares of the biopharmaceutical company’s stock worth $286,000 after purchasing an additional 20,089 shares in the last quarter. 99.14% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3295841/alder-biopharmaceuticals-aldr-stock-price-down-3.html.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Bacanora Lithium Plc  Given Average Recommendation of “Hold” by Analysts
Bacanora Lithium Plc Given Average Recommendation of “Hold” by Analysts
Summit Therapeutics  Given Consensus Rating of “Buy” by Analysts
Summit Therapeutics Given Consensus Rating of “Buy” by Analysts
Analysts Set Iteris, Inc.  PT at $9.50
Analysts Set Iteris, Inc. PT at $9.50
Head-To-Head Contrast: CVR Energy  versus Suncor Energy
Head-To-Head Contrast: CVR Energy versus Suncor Energy
Head-To-Head Contrast: Universal Technical Institute  and The Competition
Head-To-Head Contrast: Universal Technical Institute and The Competition
Reviewing XPO Logistics  & DSV
Reviewing XPO Logistics & DSV


© 2006-2018 Ticker Report. Google+.